Chronic Myelogenous Leukemia: Monitoring Response to Therapy

Posted by rob on March 5, 2011 under Uncategorized | Comments are off for this article

Abstract  Molecular monitoring is a key component of the management of patients with chronic myeloid leukemia. The current recommendation
is that molecular monitoring be performed in place of cytogenetic assessment when a major molecular response (MMR) is achieved.
With the more potent kinase inhibitors nilotinib and dasatinib now approved as front-line therapy, more patients will achieve
an MMR and will benefit from molecular monitoring. There is a strong correlation between certain BCR-ABL1 levels and the cytogenetic response, which means that molecular monitoring may act as a surrogate for cytogenetic response,
but only if the BCR-ABL1 values are converted to the international reporting scale. Furthermore, improvements in the limit of BCR-ABL1 detection and reduction of in…
More